These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 11966672)

  • 1. Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19.
    Cho JY; Yu KS; Jang IJ; Yang BH; Shin SG; Yim DS
    Br J Clin Pharmacol; 2002 Apr; 53(4):393-7. PubMed ID: 11966672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19.
    Yu KS; Yim DS; Cho JY; Park SS; Park JY; Lee KH; Jang IJ; Yi SY; Bae KS; Shin SG
    Clin Pharmacol Ther; 2001 Apr; 69(4):266-73. PubMed ID: 11309556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes.
    Yasui-Furukori N; Takahata T; Nakagami T; Yoshiya G; Inoue Y; Kaneko S; Tateishi T
    Br J Clin Pharmacol; 2004 Apr; 57(4):487-94. PubMed ID: 15025747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP2C19 genotypes and omeprazole metabolism after single and repeated dosing when combined with clarithromycin.
    Zhou Q; Yamamoto I; Fukuda T; Ohno M; Sumida A; Azuma J
    Eur J Clin Pharmacol; 1999 Mar; 55(1):43-7. PubMed ID: 10206083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes.
    Saito M; Yasui-Furukori N; Uno T; Takahata T; Sugawara K; Munakata A; Tateishi T
    Br J Clin Pharmacol; 2005 Mar; 59(3):302-9. PubMed ID: 15752376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations.
    Uno T; Niioka T; Hayakari M; Yasui-Furukori N; Sugawara K; Tateishi T
    Eur J Clin Pharmacol; 2007 Feb; 63(2):143-9. PubMed ID: 17203292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formation of omeprazole sulphone but not 5-hydroxyomeprazole is inhibited by grapefruit juice.
    Tassaneeyakul W; Vannaprasaht S; Yamazoe Y
    Br J Clin Pharmacol; 2000 Feb; 49(2):139-44. PubMed ID: 10671908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonlinear kinetics after high-dose omeprazole caused by saturation of genetically variable CYP2C19.
    Rost KL; Roots I
    Hepatology; 1996 Jun; 23(6):1491-7. PubMed ID: 8675169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ticlopidine decreases the in vivo activity of CYP2C19 as measured by omeprazole metabolism.
    Tateishi T; Kumai T; Watanabe M; Nakura H; Tanaka M; Kobayashi S
    Br J Clin Pharmacol; 1999 Apr; 47(4):454-7. PubMed ID: 10233213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole.
    Yin OQ; Tomlinson B; Waye MM; Chow AH; Chow MS
    Pharmacogenetics; 2004 Dec; 14(12):841-50. PubMed ID: 15608563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics.
    Ishizawa Y; Yasui-Furukori N; Takahata T; Sasaki M; Tateishi T
    Clin Pharmacokinet; 2005; 44(11):1179-89. PubMed ID: 16231968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omeprazole as a CYP2C19 marker in Chinese subjects: assessment of its gene-dose effect and intrasubject variability.
    Yin OQ; Tomlinson B; Chow AH; Waye MM; Chow MS
    J Clin Pharmacol; 2004 Jun; 44(6):582-9. PubMed ID: 15145965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose omeprazole: use of a multiple-dose study design to assess bioequivalence and accuracy of CYP2C19 phenotyping.
    Kovacs P; Edwards DJ; Lalka D; Scheiwe WM; Stoeckel K
    Ther Drug Monit; 1999 Oct; 21(5):526-31. PubMed ID: 10519449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Finasteride 1 mg has no inhibitory effect on omeprazole metabolism in extensive and poor metabolizers for CYP2C19 in Japanese.
    Yasumori T; Narita H; Matsuda T; Takubo T; Ogawa M; Ishii M; Hara K; Ishii Y; Okuyama K; Fujimoto G; Ochiai H; Kano A; Hasegawa S; Sato K; Taniguchi T
    Eur J Clin Pharmacol; 2006 Nov; 62(11):939-46. PubMed ID: 16953457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine.
    Miura M; Tada H; Yasui-Furukori N; Uno T; Sugawara K; Tateishi T; Suzuki T
    Br J Clin Pharmacol; 2005 Jul; 60(1):61-8. PubMed ID: 15963095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype.
    Chang M; Dahl ML; Tybring G; Götharson E; Bertilsson L
    Pharmacogenetics; 1995 Dec; 5(6):358-63. PubMed ID: 8747407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereoselective 4'-hydroxylation of phenytoin: relationship to (S)-mephenytoin polymorphism in Japanese.
    Ieiri I; Mamiya K; Urae A; Wada Y; Kimura M; Irie S; Amamoto T; Kubota T; Yoshioka S; Nakamura K; Nakano S; Tashiro N; Higuchi S
    Br J Clin Pharmacol; 1997 Apr; 43(4):441-5. PubMed ID: 9146858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carbamazepine treatment induces the CYP3A4 catalysed sulphoxidation of omeprazole, but has no or less effect on hydroxylation via CYP2C19.
    Bertilsson L; Tybring G; Widén J; Chang M; Tomson T
    Br J Clin Pharmacol; 1997 Aug; 44(2):186-9. PubMed ID: 9278208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal dose of omeprazole for CYP2C19 extensive metabolizers in anti-Helicobacter pylori therapy: pharmacokinetic considerations.
    Kita T; Sakaeda T; Aoyama N; Sakai T; Kawahara Y; Kasuga M; Okumura K
    Biol Pharm Bull; 2002 Jul; 25(7):923-7. PubMed ID: 12132671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status.
    Uno T; Shimizu M; Yasui-Furukori N; Sugawara K; Tateishi T
    Br J Clin Pharmacol; 2006 Mar; 61(3):309-14. PubMed ID: 16487224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.